BERKELEY, Calif., July 14, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced positive results from single dose and multiple dose subcutaneous arms of the randomized, placebo-controlled U.S. Phase 1 clinical trial of XOMA 052 in Type 2 diabetes patients. Of the 98 patients evaluated in different parts of the Phase 1 clinical trial, XOMA is reporting today on the 26 patients who received active drug in both single and multiple doses by subcutaneous route of administration and all 17 placebo patients. The results continue to demonstrate that XOMA 052 is well tolerated in patients. Further, a multiple dose regimen of XOMA 052 showed clinically meaningful reductions in glycosylated hemoglobin, HbA1c, and high sensitivity C-reactive protein, hsCRP, compared to a single dose regimen. Generally, a more consistent response was seen across patients in the multiple dose regimen compared to single dose regimen. New positive biological activity was observed with sustained improvements noted in fasting blood glucose, with a reduction of 29 mg/dL at day 84, equating to approximately a 1% reduction in HbA1c, and standard biomarkers of systemic inflammation and cardiovascular risk. Pharmacokinetic results continue to support monthly or less frequent dosing and drug bioavailability in patients by subcutaneous injection was 62-70% compared to IV administration. These Phase 1 results support XOMA’s plan to begin Phase 2 testing of XOMA 052 in Type 2 diabetes in the current quarter.
